Search for a trial

Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymus -LUNA Trial

To evaluate the efficacy of pasireotide LAR and everolimus alone or in combination in progressive patients with a well differentiated neuroendocrine tumor of the lung or thymus.

A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues.

To compare the long term efficacy of pasireotide LAR vs. octreotide LAR at month 6 in controlling diarrhea and/or flushing in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by the maximum…

A SINGLE ARM OPEN LABEL INTERNATIONAL MULTI CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT®) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS.

Evaluating the efficacy and safety of sunitinib in patients with progressive, advanced/metastatic well-differentiated, unresectable pancreatic neuroendocrine tumors.

First International Randomized Study in MAlignant Progressive Pheochromocytoma and Paraganglioma

Primary objective: To determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous…

A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET)

To determine whether treatment with RAD001 10 mg/d plus best supportive care prolongs the progression free survival (PFS) compared to treatment with Placebo plus best supportive care in patients with advanced pancreatic neuroendocrine tumor.

AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION
PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB
STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE
POTENTIAL TO BENEFIT FROM SUNITINIB TREATMENT

The objective of the study is to provide access to sunitinib treatment for patients who have completed a prior sunitinib study and are judged by the investigator to have the potential to benefit from sunitinib treatment. During this study the…

Immunological determinants of human embryo implantation: an ex vivo model

We intend to employ an ex vivo model of human implantation to study the factors involved in successful implantation. By linking parameters of successful implantation with embryo quality markers, we aim to improve embryo selection and IVF outcomes.…

Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients

The aim of this prospective proof-of-concept study is to increase the expression of the SSTR2 in NET patients with negative or low expression to levels amenable for somatostatin analogue treatment through the use of epigenetic drugs.

Improving peptide receptor radionuclide therapy with poly ADP ribose polymerase inhibitor.

This study has been transitioned to CTIS with ID 2024-513007-14-00 check the CTIS register for the current data. The current trial aims to asses the safety of this combination in a phase I trial with olaparib dose escalation during two cycles of…

A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α related Genetic Alterations

This study has been transitioned to CTIS with ID 2023-504853-11-00 check the CTIS register for the current data. To evaluate the ORR of belzutifan per RECIST 1.1 by blinded independent central review (BICR).

Biomarker identification of radionuclide therapy-induced radiation responses.

This is a pilot study to validate the possibility of determining the effect of PRRT with 177Lu-DOTATATE on transcriptional regulation and DNA damage induction in PBMCs and how this is related to the radiation dose.We will also want to explore if we…

Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo®; Ipilimumab, Yervoy®) versus observation

Primary objective:To estimate the efficacy of adjuvant nivolumab monotherapy in completely resected MCC patients; i.e. the primary endpoint is Disease-free survival (DFS) in arm A at 12 months, defined as the number of patients alive and free of…

An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy

To determine the objective response rate (ORR) (complete response and partialresponse) of RAD001 10 mg po qd monotherapy in patients with advanced(unresectable or metastatic) pancreatic NET after the failure of cytotoxicchemotherapy.